Trial Profile
Does the addition of trastuzumab (HER-2/neu inhibition) to fulvestrant therapy improve response in women with advanced breast cancer.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 May 2015
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Breast cancer
- Focus Therapeutic Use
- 06 May 2015 New trial record